Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study-Reference-Cited by-同舟云学术

Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study

Published:2021-09-15 Issue:1 Volume:15 Page:172-181
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Mazza Stefano¹,Piazza O. Sed Nicole¹,Conforti Francesco Simone¹,Fascì Alberto¹²,Rimondi Alessandro²,Marinoni Beatrice²,Casini Valentina³,Ricci Chiara⁴,Munari Francesca³,Pirola Lorena⁵⁶,Invernizzi Pietro⁵⁶,Girelli Carlo⁷,Lupinacci Guido⁸,Pastorelli Luca⁹¹⁰,Cavallaro Flaminia¹,Ferraris Luca¹¹,Colucci Alice¹¹,Amato Arnaldo¹²,Eugenio Tontini Gian¹²,Vecchi Maurizio¹²,Fiorino Gionata¹³¹⁴,Caprioli Flavio¹²

Affiliation:

1. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit Milan Italy

2. Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan Italy

3. Gastroenterology Unit Bolognini Hospital Bergamo Italy

4. Department of Clinical and Experimental Sciences University of Brescia Spedali Civili Brescia Italy

5. Division of Gastroenterology and Center for Autoimmune Liver Diseases Department of Medicine and Surgery University of Milano‐Bicocca Monza Italy

6. European Reference Network on Hepatological Diseases (ERN RARE‐LIVER) San Gerardo Hospital Monza Italy

7. Gastroenterology and Digestive Endoscopy Unit Busto Arsizio Hospital Varese Italy

8. Gastroenterology and Endoscopy Unit Ospedale Maggiore Crema Italy

9. Gastroenterology and Liver Unit ASST Santi Paolo e Carlo Ospedale San Paolo Milan Italy

10. Department of Health Sciences Univeristà degli Studi di Milano Milan Italy

11. Gastroenterology and Endoscopy Unit Gallarate Hospital Varese Italy

12. Gastroenterology and Digestive Endoscopy Unit Valduce Hospital Como Italy

13. IBD Center Humanitas Clinical and Research Center Milan Italy

14. Department of Biomedical Sciences Humanitas University Milan Italy

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13131

Reference30 articles.

1. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

2. The PROSIT-BIO Cohort

3. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

4. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

5. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

3. Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching;BioDrugs;2024-03-23

4. Evaluation of selected serum biomarkers levels in response to the infliximab reference product (Remicade®) versus its biosimilar (Remsima®) in a sample of ulcerative colitis patients: a cross-sectional study;F1000Research;2023-12-06

5. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus;Journal of Clinical Medicine;2023-10-03